Back

Patient Explorers

Regular users

Current State

I do have patients that complain about symptoms returning before their next injection. I sometimes switch to Dysport® if the patient has been treated previously with Botox or Xeomin.

Desired State

Now my patients have reported positive experiences with Dysport®, I’m motivated to switch more of my patients that are not achieving their goals, and may consider Dysport® in BoNT-A-naive patients

target

Messaging should clearly demonstrate how Dysport® enhances patient outcomes and the patient experience.

Communication objective associated: Raise correlation between Dysport® symptom control achievement and dosing

  1. The Dysport® duration of effect may be positively correlated with dose, which in turn correlates with a greater amount of active neurotoxin administered9
  2. In ULIS‑III, real‑world upper‑limb cohorts showed significantly longer intervals between injections with Dysport® than with other BoNT‑As in upper limb spasticity
  3. AboLiSh (16‑month observational, LLS): effectiveness set mean reinjection interval ≈ 18.3 ± 6.1 weeks, with clinically meaningful cumulative goal gains over cycles—so routine practice also supports longer spacing in ambulatory LLS

Key supportive study:

  • High amount of neurotoxin: . Field M, et al. Toxins. 2018;10:535
  • ULIS III : Turner-Stokes L et al., J Rehabil Med. 2021;53(1):jrm00133
  • AboLiSh : Esquenazi A et al., Arch Phys Med Rehabil. 2024.

Key material:

  • CLM presentation

Digital material for follow up:

  • Esquenazi webinar
  • Jacinto reflection 
  • VAE on duration of response (to come)

Communication objective associated: Raise correlation between Dysport® symptom control achievement and dosing/injection technique

  1. Dysport® has a dose-response effect16
  2. Dysport® treatment can be tailored to suit each patient’s needs—optimizing dosing and injecting technique to create a better experience for the patient
  3. Recommended doses for upper/lower limb muscles

Key supportive study :

  • Upper limb : Gracies J, et al. Muscle Nerve. 2018;57(2):245-254
  • Lower limb : Gracies J, et al. Neurology. 2017;89(22):2245-2253
  • Abolish : Esquenazi A, et al. Arch Phys Med Rehabil. 2024

Key material:

  • CLM presentation
  • Dosing app
  • FIT guide

Digital material for follow up:

  • Ixcellence website – Echo modules

Communication objective associated: Emphasize that Dysport® has broad applicability across eligible patient types which makes it the toxin of choice

  1. You have the power to deliver lasting control between treatment cycles and help prevent the early return of debilitating symptoms
  2. IXCELLENCE: the IPSEN Neuroscience HCP Training Program on the use of Dysport and spasticity management
  3. IXCELLENCE website to support you in your training journey with Dysport
  4. Dosing app to support you selecting the right dose at the right time

Key material

  • CLM presentation (slide 5,10,25,47)
  • Dosing app
  • Ixcellence website
  • FIT guide

Digital material for follow up

  • Invitation to (inter)national training
  • Dosing app guide (to come)

Communication objective associated: Emphasize that Dysport® has broad applicability across eligible patient types which makes it the toxin of choice

  1. You have the power to deliver lasting control between treatment cycles and help prevent the early return of debilitating symptoms
  2. IXCELLENCE: the IPSEN Neuroscience HCP Training Program on the use of Dysport and spasticity management
  3. IXCELLENCE website to support you in your training journey with Dysport
  4. Dosing app to support you selecting the right dose at the right time

Key material

  • CLM presentation (slide 5,10,25,47)
  • Dosing app
  • Ixcellence website
  • FIT guide

Digital material for follow up

  • Invitation to (inter)national training
  • Dosing app guide (to come)

Communication objective associated: Emphasize that Dysport® has broad applicability across eligible patient types which makes it the toxin of choice

  1. You have the power to deliver lasting control between treatment cycles and help prevent the early return of debilitating symptoms
  2. IXCELLENCE: the IPSEN Neuroscience HCP Training Program on the use of Dysport and spasticity management
  3. IXCELLENCE website to support you in your training journey with Dysport
  4. Dosing app to support you selecting the right dose at the right time

Key material

  • CLM presentation (slide 5,10,25,47)
  • Dosing app
  • Ixcellence website
  • FIT guide

Digital material for follow up

  • Invitation to (inter)national training
  • Dosing app guide (to come)